When UC Berkeley biochemist Jennifer Doudna first began studying how bacteria fight virus infections, she had no idea it ...

KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting ...

Disease development is often shaped by genetics, with how much or how little a gene is expressed influencing disease risk.

According to The New England Journal of Medicine, investigators at Uppsala University Hospital implanted a product called ...

So, even via the more modest predictions, people will be able to double their longevity. When you reach 100 years old, you ...

If approved, Regeneron and Tessera's TSRA-196 could become the first curative therapy to reach patients with AATD, who have ...

Meta: \{"__typename":"TimeAuthorPageMetadata","title":"Markham Heid \| TIME","description":"Read the latest stories by ...

A new FDA pathway could speed bespoke gene therapies, but key questions over scope and commercial viability remain.

As of November 27, CRISPR Therapeutics AG (NASDAQ:CRSP) has a moderately positive opinion, with 60% analysts covering it having a Buy or equivalent rating. With a consensus 1-year median price target ...

This year has seen the approval of several first-in-class therapies for HAE, but in a fragmented space, experts question ...

To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...

Teens at a Georgia high school may have come up with a better way to detect and treat Lyme disease. They took their idea to ...